

"This is an, un-copied, author manuscript that has been accepted for publication in the *Frontiers in Bioscience*". Cite this article as appearing in the *Journal of Frontiers in Bioscience*. Full citation can be found by searching the *Frontiers in Bioscience* (<http://bioscience.org/search/authors/htm/search.htm>) following publication and at PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed>) following indexing. This article may not be duplicated or reproduced, other than for personal use or within the rule of "Fair Use of Copyrighted Materials" (section 107, Title 17, U.S. Code) without permission of the copyright holder, the *Frontiers in Bioscience*. From the time of acceptance following peer review, the full final copy edited article of this manuscript will be made available at <http://www.bioscience.org/>. The *Frontiers in Bioscience* disclaims any responsibility or liability for errors or omissions in this version of the un-copied manuscript or in any version derived from it by the National Institutes of Health or other parties."

## Cancer vaccines: Uses of HLA transgenic mice compared to genetically modified mice

Stephanie McArdle

*The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS*

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Transplantable tumor in mice transgenic for human MHC molecules
4. Genetically engineered mice spontaneously developing tumors
5. Conclusion
6. Acknowledgements
7. References

### 1. ABSTRACT

Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the discovery of peptides derived from tumor antigens many of which have since been used in clinical trials with varying degrees of success. Although these models are not perfect, they nonetheless allow transplantable tumor models to be developed to evaluate novel vaccination strategies that can then be applied in humans. In addition animals that have been genetically modified to “spontaneously” generate tumors that will grow within their correct environment are of greater value for studying angiogenesis, metastasis and the relationship between the immune system and tumor in a physiological setting. In this review, mice genetically modified to express HLA genes or to spontaneously develop tumors are discussed, highlighting their advantages and limitations as preclinical models for cancer immunotherapy.

### 2. INTRODUCTION

Cancer is a diverse group of diseases characterized by indefinite and uncontrolled cell proliferation. Overall one can say that tumor development is the result of a series of genetic alterations which have occurred in a multistep fashion within one cell over many years eventually leading to the emergence of a clone which no longer responds to its environment nor is controlled by the same signals that govern normal cell growth. As a consequence of such genetic changes, cell signaling and regulatory pathways in transformed cells are disturbed, giving growth advantages, modifying the micro-environment of the tumor cells and promoting escape mechanism from immunosurveillance. In addition, very early on in the disease progression, new blood vessels are created; inflammatory cells are recruited and activated in the surrounding stroma of the tumor. The interactions between tumor cells, immune cells, blood vessels and stroma cells are very complex and it is not possible to reproduce and study them in *in vitro* cell cultures. This is where mouse models of cancer, including genetically engineered mice (transgenic) and transplantable tumor models have proved indispensable tools to investigate the molecular and cellular mechanisms of tumor growth, as well as their applications in cancer research. Indeed, in spite of the various advances in the diagnosis and treatment of cancer, the conventional modalities of treatment have been unable to significantly decrease the mortality rate in patients diagnosed with advanced disease. There is therefore a great need for additional therapy that could specifically eliminate tumor cells whatever their location in the body but leave healthy tissue intact. Immunotherapy aims at manipulating/educating the patient’s own immune system to arm it against tumor cells so that only transformed cells are killed. Tumor cells differ from normal cells by the accumulation and retention of many genetic alterations such as mutation, amplification, deletion, and translocation, which leads to over-production of self proteins, re-expression of proteins normally only expressed by certain organs and/or at a certain stage of the development, or production of mutated proteins, all referred to as tumor antigens. The first human tumor antigen was MAGE-1 discovered by Thierry Boon’s lab (1); since then many more candidate genes have been added to the list.

All proteins produced by the cell, whether normal or abnormal, are degraded by enzymes complexes called proteasomes. This proteasomal machinery generates numerous peptides, which are then associated with newly synthesized Major Histocompatibility Complex (MHC) class-I molecules and subsequently transported to the cell surface. Most nucleated cells will express MHC class-I molecules and these are consistently surveyed by CD8<sup>+</sup> T cells. Extracellular proteins are, on the other hand, first internalized by antigen presenting cells, by endocytosis or phagocytosis, encapsulated into endosomes and then degraded in the endocytic vacuoles. A phenomenon referred to as “cross-priming” can also occur where exogenous proteins are either processed by the proteasome thereby joining the class-I pathway or are first cleaved using the class-II pathway but then get transferred into the endoplasmic reticulum where they are trimmed further to fit into the groove of MHC class-I (2). The majority

of peptides resulting from endocytic digestion however will bind to MHC class II molecules, which are mainly expressed by monocytes, macrophages, dendritic cells and B-cells and are surveyed by CD4<sup>+</sup> T cells.

One of the first steps needed to initiate the cascade of events that will eventually lead to an immune response is the physical interaction between the T-cell receptor (TCR) on the surface of a T lymphocyte and an antigenic peptide on the surface of an antigen presenting cell. TCRs interact with peptides “presented” by cell-surface MHC molecules. Foreign peptides presented on a cell, for example following viral infection, are recognized by T cells specific for these peptides and the cell is destroyed by cytolytic or apoptotic-induced mechanisms. Neo-antigens (abnormal self proteins arising during neoplastic transformation) may be recognized by the immune system as foreign and are potential targets for T cell mediated cellular killing. It is therefore of considerable importance to identify immunogenic and naturally (endogenously) processed MHC class-I and class-II peptides derived from tumor antigens in order to assess their potential as vaccines against cancer. It is also essential to learn more about the immune system / tumor relationship in a setting that resemble human tumor to understand the immune mechanisms of tumor rejection.

This review describes how HLA transgenic mice and genetically engineered mice developing spontaneous cancer can help answer specific questions, important for the generation of future cancer vaccines. However both models have many advantages and disadvantages and those are briefly summarized in Table 1.

### 3. TRANSPLANTABLE TUMOURS IN MICE TRANSGENIC FOR HUMAN MHC MOLECULES

There are a number of different approaches that can be adapted for the identification of new MHC class I/II-restricted target antigens for immunotherapy and many of these are in fact complementary.

HHDII transgenic mice provide a good model for the study of HLA-A2 restricted T cells responses *in vivo* (3). These animals are “knockout” for H-2 genes, expressing instead an MHC class I molecule, consisting of the human HLA-A2.1  $\alpha 1$  and  $\alpha 2$  domains, the murine H-2Db $\alpha 3$ , transmembrane and cytoplasmic class I heavy chain regions which have been covalently linked to human  $\beta 2$ -microglobulin, allowing for HLA-A2 restricted antigens presentation within the context of the murine immune system (3). These mice have been shown to have an improved capacity to mount HLA-A2-restricted CTL responses compared with HLA-A2 transgenic mice (HLA-A2<sup>+/+</sup>/human beta2m<sup>+/+</sup>) that still express endogenous murine H-2b class I molecules (4). They represent a versatile animal model for CTL epitope mapping and preclinical characterization of HLA-A2-restricted CTL responses. Using HHDII transgenic mice, we have screened the Prostatic Acid Phosphatase (PAP) and HAGE proteins for immunogenic HLA-A2-derived peptides and defined three novel epitopes (5, 6). This was confirmed and expanded by Machlenkin *et al* who were able to show that the class-I PAP-derived peptide (PAP135) pulsed onto dendritic cells could delay tumor growth in a preventative setting but also, and more importantly, could increase survival of mice bearing palpable tumor at the time of vaccination (7). Although CTL generated in HHDII mice were able to kill appropriate target cells pulsed with peptide, they were unable to kill human HLA-A2+ targets naturally expressing the antigen of interest. This is probably due to the fact that, unless CD8<sup>+</sup> T cells generated are of very high avidity for the peptide, the recognition of the target cells by CD8<sup>+</sup> T cells requires not only contact between the MHC/peptide and TCR but also between the CD8 chain and the  $\alpha 3$  domain of the MHC class I molecule from the same species. This would explain why several *in vitro* stimulations are necessary to obtain murine CD8<sup>+</sup> T cells capable of killing antigen expressing human cancer cells (8). Still using the HHDII mice as a screening model, it is possible to assess the immunogenicity of several peptides as well as various modified peptide and even the immunogenicity of different fractions of peptides eluted from tumor cells upon the generation of CTL (9, 10). CTL generated with peptides modified at critical anchoring position, which would increase their binding affinity to specific HLA haplotypes, have been shown not only to recognize and kill target cells pulsed with the modified peptide but also recognize and kill target cells pulsed with the wild type sequence (9). Moreover HHDII mice have proved to be a useful model to study, assess, and compare the efficiency of different vaccines such as naked plasmid DNA encoding either multi-epitopes for HLA class-I and class-II peptides, or whole protein sequence either in a single agent or in a prime-boost regimen (11, 12). We have, ourselves, been able to show CTL activities of splenocytes from HHDII mice immunized with gold labeled DNA encoding the entire human mutated (at position 273) p53 protein and stimulated once *in vitro* with peptide 65, 149, 264 and 217 against RMA/2 cells pulsed with the same peptides with the exception of RMA/2 cells pulsed with the 264 peptide which were not killed (13). These results are in accordance with previously published work where peptide 264 was reported not to be naturally processed from p53 protein mutated at position 273 (14). It is therefore possible to use HHDII mice not only to identify immunogenic peptides but also and more importantly, to test whether these are endogenously processed from natural or mutated cancer protein and although the emphasis in this review is on HLA-A2 transgenic mice, HLA-A2 being the most common class-I allele, other HLA transgenic mice also exist and have also been used (Table 2). Some authors have, however, reported that the peptide repertoire resulting from the endogenous processing of the HPV derived protein by the HHDII mice may differ to that of human and caution should be taken when extrapolating the data obtained using these mice to human (15). It is therefore important to verify data obtained in these mice using PBMCs from healthy donors and/or cancer patients.

Cerundolo’s group used the inability of conventional human HLA-A2 tetramers to bind to the murine CD8 molecules in the HHDII mice to show that high avidity T cells which are independent of CD8 binding can be specifically identified and isolated from these mice (16). The group then produced HLA-A2 tetramer engineered to lack the human CD8 binding capacity in order to demonstrate selective binding of these tetramers to high avidity human CTL (16). The avidity of a given T cell clone is

the resulting strength of the overall interactions of MHC/peptide (binding affinity) and TCR, co-stimulatory molecules and the extracellular microenvironment. High avidity has been linked with T cell priming and its response to a given antigen. A correlation between the overall avidity and the ability of a T cell clone to recognize and kill tumor cells has also been shown (17). This avidity is generally broadly measured by the antigen dose required to induce a T cell response, where low amounts of antigen (>100 nM peptide loaded on antigen presenting cells) are required for high avidity T cell generation. These results are of great importance since cancer can be viewed as a chronic disease and TCR affinity/avidity has been shown to be the primary driving force underlying repertoire of chronic antigenic stimulation (18).

HLA class II transgenic mice were first designed to study auto-immune disease (19, 20, 21). Although, it is now accepted that CD4<sup>+</sup> T cells play a major role in initiating and maintaining CD8<sup>+</sup> immune responses (22) as well as helping in the development of memory CD8<sup>+</sup> T cells (23). More recently, Sherman's group were able to demonstrate yet another role to these cells, that of facilitating entry of CD8<sup>+</sup> T cells into the tumor microenvironment (24). Only a limited number of T-helper epitopes have been identified to date (25, 26). With this in mind, HLA class II transgenic mice expressing HLA class II molecules in the absence of murine class II molecules (A $\beta$ <sup>0/0</sup>) have been generated and used for the screening of immunogenic HLA class II peptide epitopes of variable chain length. HLA-DR4<sup>+/+</sup>/IE<sup>0/0</sup> and HLA-DR1/IE<sup>0/0</sup> transgenic mice are such mice and can be used to study human CD4<sup>+</sup> T cell immune response (27) as well as for the identification of MHC class II peptides. These mice have also recently been shown to have an enhanced efficacy over the HLA-DR1<sup>+/+</sup>/IAbeta<sup>+/+</sup> mice (22, 23). Using these HLA-DR4<sup>+/+</sup>/IE<sup>0/0</sup> and HLA-DR1<sup>+/+</sup>/IE<sup>0/0</sup> mice we have successfully identified four novel class-II derived peptides derived from p53, PAP and HAGE proteins (5, 6, 30). We were, indeed able to show specific HLA-DR-restricted proliferation and cytokine production by splenocytes derived from p53, PAP or HAGE peptide immunized animals. Moreover mature BM-DC pre-pulsed with p53 overexpressing tumor lysate were recognized by CD4<sup>+</sup> T cells generated with the same peptide. The immunogenicity of these HLA-DR-restricted peptides was subsequently confirmed using HLA-DR4/DR1 PBMC from healthy donors, reinforcing the value of utilizing HLA transgenic mice as a pre-screening method (30).

Overall, we and others have found that HLA transgenic mice recognize the same antigenic determinants as those recognized by human T cells (31, 32) demonstrating the usefulness of such mice in finding natural tumor derived or virally derived epitopes that can be used in clinical trials.

There has been considerable interest in the generation of mice, which are transgenic for both human class I and class II molecules and knockout for the murine class I and class II molecules and some have succeeded. Indeed, the HHDII/DR1 mice are not only double transgenic for HLA-A2 and HLA-DR1 but are also double knockout meaning that these mice survive with only human MHC molecules expressed on the surfaces of their cells. Using these mice, we were able to show that specific class-I and class-II responses can be generated simultaneously after immunization with BM-DC transiently transfected with HAGE plasmid (Figure 1). Indeed splenocytes derived from HHDII/DR1 transgenic mice immunized with one round of mature syngeneic Bone-marrow derived dendritic cells (BM-DC) transfected to express the HAGE protein and stimulated once *in vitro* with either peptide HAGE126, HAGE338 or HAGE 506 were assessed for both cytotoxic responses and proliferation. Specific killing in those stimulated *in vitro* with HAGE126 could be demonstrated reaching almost 40% of total cell lysis in four out of six mice tested (Figure 1A). As a control experiment, HHDII/DR1 transgenic mice received one round of syngeneic BM-DC transfected with an empty plasmid and splenocytes were re-stimulated *in vitro* with peptide HAGE126. No cytotoxic response was achieved in both mice tested indicating that CD8<sup>+</sup> T cell responses observed earlier were actually due to the immunization with syngeneic BM-DC expressing HAGE and not the *in vitro* re-stimulation (Data not shown). Moreover, supernatants from the *in vitro* re-stimulation culture were harvested on day 3 and day 5 to measure IFN $\gamma$  production by ELISA. Peptide HAGE126 allowed significant levels of peptide-specific IFN $\gamma$  secretion on both days. These results were later confirmed when HHDII/DR1 mice were immunized with one round of syngeneic BM-DC pulsed with a HAGE-positive K562 cell lysate, and *in vitro* re-stimulation with HAGE126 peptide. Indeed, peptide-specific cytotoxic response of 25% was achieved in one out of two mice (Data not shown). Splenocytes re-stimulated *in vitro* with peptides HAGE338 or HAGE 506 for one week followed by CD8<sup>+</sup> depletion and a week of rest with the presence of low level of murine IL-2 in the media were then co-cultured with BM-DC matured overnight with LPS and for 2 hours the next day with PolyIC prior to the addition of the peptide. Cultures were incubated for approximately 60 hours at 37°C, and (<sup>3</sup>H)-thymidine was added at 37kBq/well in the last 18 hours of incubation. Plates were harvested onto 96 Uni/Filter plates (Packard), the scintillation liquid (Microscint 0, Packard) was added and the plates were counted on a Top-Count counter (Packard). Specific proliferation was observed with both peptides HAGE 338 and HAGE 506-II (Figure 1B and 1C). This proliferation was shown to be HLA-DR restricted since the addition of an HLA-DR antibody (L243) could inhibit the proliferation whereas the isotype control could not. Specific release of IFN $\gamma$  was also observed with both peptides mainly on day 3 with however also a production of IL-5 by peptide HAGE338 but only on day 3 (data not shown).

Some groups have also been able to generate mice transgenic for class I molecules as well as a tumor antigen (33). Both of these models will prove extremely useful for investigating the role of CD4<sup>+</sup> T cells in the generation of CTL and their anti-tumoral effect. These mice will also allow the study of tolerance towards tumor antigens and subsequently ways of overcoming it; the answer of which will bring us closer to a better immunotherapeutic strategy for the treatment of human cancer.

Single and now double transgenic mice expressing only human HLA molecules can therefore be used to screen potential immunogenic epitopes, as well as assessing many different strategies for cancer vaccinations. These can include

peptides, “string” of peptides or DNA/virus based vaccines administered in a prime boost regimen with different adjuvants. Indeed, DNA based therapy using 12 peptides derived from the HER2/ErbB-2 gene was shown not only to induce peptide specific CTL responses in both HHDII mice and HLA-A2 human *in vitro* stimulated PBMC but was also capable of significantly delaying the *in vivo* growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) (34). These mice will also help towards the optimization of adoptive transfer therapy and the development of sensitive tools for the immune monitoring of the immune system for the effects of cancer immunotherapy.

The antigen processing machinery, including specific proteasomal cleavage, TAP proteins, and chaperones, in human and mouse do however differ slightly and the overall antigen digestion and transportation may give rise to different peptide repertoire in transgenic mice and in humans. It is also known that the expression of several HLA haplotypes within one cell will induce competition between peptides thereby altering the outcome of the peptide repertoire presented by a given individual and thus rendering it different to the one found using HLA-single or double transgenic mice.

Importantly all these studies rely on the use of transplantable tumors, which although useful to address some very precise questions, are limited when it comes to studying/targeting the local microenvironment including newly grown blood vessels feeding the tumor and the metastases. In these cases, transplantable tumors will be of no real use since most of them rarely metastasize and do not have the same relationship with their immediate surrounding due to their artificial implantation at a site which differs to the one where they originated. In an attempt to remediate to this downfall of transplantable tumors, Rosenblatt’s group established a very elegant model of breast cancer metastasis where both the breast cancer cells and the bone target are of human origin (35). In this model the engrafted human bone was shown to be functional with B cells and human IgG detected in the blood stream of the mice. Moreover, the injection of a human cell line derived from a metastatic nodule of a breast cancer patient induced metastasis to the human engrafted bone and lung of the mice. This model is thereby unique in its capability of reproducing the physiological events observed in breast cancer patients with bone metastasis and it will therefore become possible to better understand osteotropism, mechanism which commonly occurs in breast and prostate cancer but for which only a mice prostate cancer model was available.

#### 4. GENETICALLY ENGINEERED MICE SPONTANEOUSLY DEVELOPING TUMOURS

Mouse models for cancer have existed for more than a century with the initial model being the “tumor prone inbred mice” where mice susceptible to developing tumors were bred over and over until the establishment of a strain of mice with high incidence of developing spontaneous or carcinogen-induced tumor was achieved (36). Thereafter advancement in genetic manipulation, has made it possible to genetically modify specific genes using gene targeting strategies in order to obtain mice, engineered for conditional gene expression of transforming genes, such as SV40 or polyomas, in a specific tissue (e.g the transgenic adenocarcinoma mouse prostate cancer model: TRAMP). Others have been genetically manipulated so that a cell or tissue-specific promoter will drive the expression of an oncogene known to be at the origin of tumor formation (e.g. breast cancer model: where HER2/neu gene is under the control of the mouse mammary tumor virus (MMTV) promoter/enhancer (37)). Both systems generate mice with tumors that will spontaneously develop in a particular organ and many models have been generated; Table 3 highlights many of them. These may not, however, match exactly the origin of the cell type found in human tumors; indeed, TRAMP mice, for example, develop prostate tumors of seminal origin instead of an epithelial one. However, those tumor models offer the advantage of spontaneously developing in the organ of interest. They also provide information that may be more relevant to cancer development in humans where the tumor is initiated *in vivo* by the clonal expansion from a single cell. Moreover injection of numerous tumor cells, as in the case of transplantable tumor models, may trigger inflammatory signals which may act in favor of the development of appropriate immune responses or may instead promote immuno-editing leaving behind immune-resistant subclones. By contrast, spontaneous tumors develop in a slow, progressive manner that may evoke reduced immune recognition and selection. Therefore immunotherapy against these tumors can be more difficult to raise, mimicking the challenges faced when using immunotherapy against self antigens in human tumors. It is also becoming clear that the tumor microenvironment greatly influences the outcome of immunotherapy and therefore requires careful evaluation. Recently, Wall *e. al.* (38) modified the MMTV/neu model to express at the end of the rat neu gene the dominant class-I and a class-II epitopes derived from ovalbumin. These mice were further engineered and expressed then also a dominant-negative mutant of p53 (DNp53, R172H) under the control of the whey acid protein (WAP) promoter in order to accelerate tumor formation. Using this new model, they were able to show that using the same number of adoptively transferred T cells (CD4<sup>+</sup> and CD8<sup>+</sup>) both regression and non-regression responses could be obtained within the same mice, implying that these therapeutic responses were largely dictated by local, inherent properties of the tumor rather than systemic immunologic effects.

This study highlights again how important and influential the tumor microenvironment may be on the outcome of immunotherapy. Most tumor associated antigens are only expressed at certain points during tumor progression or are constitutively expressed at low level by normal cells; therefore one other major problem is the potential to develop immune tolerance, which is more likely to occur in mice developing spontaneous, slow growing tumors than transplantable tumors. Using the TRAMP model, Matteo’s group highlighted that tumor antigen in spontaneously arising tumors are indeed seen as “self” antigen and vaccination strategies such as intradermal injection of peptide-pulsed DCs can have an influence on disease progression (39); while Gilboa’s group (40), were able to demonstrate that an mRNA vaccine encoding tumor-associated antigens and GM-CSF could efficiently prime CTL responses in this model. However this was unable to overcome tolerance,

shown to occur at the thymic level (central tolerance) as a single adoptive transfer of naive wild type splenocytes prior to the first immunization led to the specific production of CTL capable of infiltrating the tumor and reducing the prostate cancer grade. It was therefore concluded that such vaccines although very efficient in generating high avidity CD8<sup>+</sup> T cells are not sufficient to generate CTL against self antigens in animals bearing spontaneous tumors. Naive T cells are known to rapidly proliferate and differentiate into effector cells (T<sub>E</sub>) shortly after encountering their appropriate antigen on antigen presenting cells *in vivo*. As the antigen is cleared, these cells will die leaving only a small fraction of residual central (T<sub>CM</sub>) and effector (T<sub>EM</sub>) memory T cells. Memory T cells persist a lifetime and can respond very quickly upon re-exposure to the same antigen by differentiating into T<sub>E</sub>. Central (T<sub>CM</sub>) and effector (T<sub>EM</sub>) memory T cells which are usually discriminated by their cell surface markers, functional characteristics and migratory properties (40). Future therapy involving adoptive transfer needs to consider carefully which memory cell subtypes are more likely to survive longer *in vivo* and their therapeutic efficacy against established tumors. Using a spontaneous gp100<sup>+</sup> murine melanoma cell line (41), Restifo's group were able to show differences between the two CD8<sup>+</sup> memory subtypes in their ability to migrate to secondary lymphoid organs and not to the tumor itself as previously thought, which is required for optimal tumor eradication. This suggests that T<sub>CM</sub> cells might be more suited for adoptive transfer against large tumors with additional tumor-antigen vaccination (42).

Another advantage of using genetically engineered mice is the possibility of studying naturally occurring metastasis, which can be targeted after removal of the primary tumor thereby getting closer to the human development of the disease. New generations of transgenic mice have since been developed which have specific somatic mutations that are induced by tissue specific and time-controlled manner. These are better models because the surrounding stroma cells are left "untouched", i.e. non-mutated by the procedure, and therefore their influence over tumor growth can then be studied with more relevance to the development of human tumors. Many different strategies have been employed to achieve this and for a more comprehensive review on this subject one can read the very good review by Jonkers and Berns (43).

However, the main drawback of many of these spontaneous models is the difficulty in generating large cohort of mice bearing tumors at the same stage of tumor development in order to perform large experiments. Results published so far were obtained when tumors were still relatively small and the question remains whether these immuno-based therapies would still be as effective against larger tumors.

## 5. CONCLUSION

In conclusion, transgenic mice for HLA molecules are useful for the identification of naturally endogenously processed immunogenic peptides derived from tumor associated antigens and can be used to assess different vaccines strategies whether these are peptide-based vaccines with strong adjuvants, DNA/virus-based vaccines, chemotherapy alone or in combination with immunotherapy. However, these models do have their limitations in mimicking the human peptides repertoire and do not take into account the "natural" micro-environment of the origin of the tumor cells which have been transplanted, also they are not subject to the same mechanisms of tolerance and most of them do not spontaneously metastasize. This is why many researchers have turned to genetically engineered mice that "spontaneously" develop tumors within the relevant tissue, although not necessarily the same cell type as found in human cancers. One future possibility would be to develop a mouse model that is transgenic for human HLA molecules and "spontaneously" develops tumors in the appropriate tissue. Such models have started to emerge with the recent generation of an HLA-A2 transgenic mice mouse model developing spontaneous melanoma by the group of Prevost-Blondel (44). Although this model is still not ideal because the site where the first tumor developed is different to that in human i.e all the mice developed ocular melanoma first, they still carry their own MHC molecules and can still help understand why although strong CD8-mediated immune responses are detected in mice with melanoma, the disease continues to progress and metastasize ultimately leading to the death of the animal. The authors have shown that MHC and antigen expression are both tumor and animal-specific with a strong overall down regulation of both of these in visceral lesions. However, it should be noted that studying the MHC expression at varying time points can alter these results. For example in this study MHC expression was determined after culturing the tumor cells *in vitro* for a few days whilst in our hands a model of transplantable colorectal cancer (CT26) in BALB-C mice showed that overnight culturing of tumors generated from progressing animals was sufficient to restore the strong down-regulation of MHC expression which was initially observed when tumor cells had been excised from the animal and stained immediately (45). It would be of interest to assess CD4<sup>+</sup> T cell involvement and more specifically the level of Treg present in these animals since systemic ignorance, anergy and immunoeediting cannot explain the growth of these cutaneous tumors.

At present time, no single mouse model will cover the full spectrum of the human disease and researchers whilst developing new models, need to bear in mind the limitations imposed by the developing tumor and its microenvironment and the differences existing between mouse and human, such as in the Toll-like receptor family (46). Toll-like receptors (TLRs) belong to a family of receptors called pattern recognition receptors (PRRs) which are used by the innate cells to recognize conserved pathogen-associated molecular patterns (PAMPs) expressed by microorganisms. To date 10 TLRs have been identified in human and 12 in mice. Their expression and stimulation have however been shown to differ between human and mice (46). Indeed TLR-2 for example which recognizes bacterial lipopeptides is present in mouse T-cells but not in human, and TLR-3 which recognizes double-stranded RNA is expressed by mouse macrophages but not human macrophages (47, 48). On the other hand TLR-4, which recognizes glycolipid of the gram-negative bacteria, although very similar in both species, is differentially regulated by

LPS. In human monocytes/macrophages incubated with LPS TLR-4 expression increases whereas it is downregulated in mouse macrophages (47).

One should therefore be very careful in trying to translate any results obtained with either model into clinic. Some scientists have even started to question the entire usefulness of these models proposing to go straight to treatment.

## 6. ACKNOWLEDGEMENTS

This work was supported by European Commission, Contracts LSHC-CT-2004-503306 (ENACT) and ESTDAB (QLRI-CT-2000-01325), the John and Lucille van Geest Foundation. We are also grateful to Stephen Reeder for excellent technical support and Morgan Mathieu for providing the HAGE data. The author wishes to thank Prof. R. C. Rees for his help in editing this manuscript.

## 7. REFERENCES

1. van der Bruggen V, C. Traversari, P. Chomez, P. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma: *Science* 254, 1643-7 (1991)
2. Palmowski M.J, U. Gileadi, M. Salio, A. Gallimore, M. Millrain, E. James, C. Addey, D. Scott, J. Dyson, E. Simpson, V. Cerundolo. Role of immunoproteasomes in cross-presentation: *J Immunol* 177, 983-90 (2006)
3. Pascolo S, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, B. Perarnau. HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice: *J Exp Med* 185 (12), 2043-51 (1997)
4. Ramage J.M, R. Metheringham, R. Moss, I. Spendlove, R. Rees, L.D. Durrant. Comparison of the immune response to a self antigen after DNA immunisation of HLA\*A201/H-2Kb and HHD transgenic mice: *Vaccine* 22, 1728-31 (2004)
5. Miles A, A. Roger, R. Parkinson, R. Rees, S.E.B. McArdle: Overview of prostate biomarkers as potential targets for immunotherapy. *Current Cancer Therapy Reviews*. In press.
6. Mathieu M.G, A.J Knights, G. Pawelec, C.L. Riley, D. Wernet, F.A. Lemonnier, P.T Straten, L. Mueller, R.C Rees, S.E. McArdle. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides: *Cancer Immunol Immunother* 56, 1885-95 (2007)
7. Machlenkin A, R. Azriel-Rosenfeld, I. Volovitz, E. Vadai, A. Lev, A. Paz, O. Goldberger, Y. Reiter, E. Tzehoval, I. Benhar, L. Eisenbach. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice: *Cancer Immunol Immunother* 56, 217-26 (2007)
8. Pascolo S, M. Schirle, B. Guckel, T. Dumrese, S. Stumm, S. Kayser, A. Moris, D. Wallwiener, H.G. Rammensee, S. Stevanovic: A MAGE-A1 HLA-A A\*0201 epitope identified by mass spectrometry. *Cancer Res.* 61, 4072-7 (2001)
9. Corbet S, H.V. Nielsen, L.Vinner, S. Lauemoller, D. Therrien, S. Tang, G. Kronborg, L. Mathiesen, P. Chaplin, S. Brunak, S. Buus, A. Fomsgaard: Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. *J Gen Virol* 84, 2409-21 (2003)
10. Gritzapis A.D, N.N. Sotiriadou, M. Papamichail, C.N. Baxevanis. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors: *Cancer Immunol Immunother* 53, 1027-40 (2004)
11. Shi T.D, Y.Z. Wu, Z.C Jia, W. Zhou, L.Y. Zou. Therapeutic polypeptides based on HBcAg (18-27) CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice: *World J Gastroenterol* 10, 1222-6 (2004)
12. Himoudi N, J.D. Abraham, A. Fournillier, Y.C. Lone, A. Joubert, A. Op De Beeck, D. Freida, F. Lemonnier, M.P. Kieny, G.J. Inchauspe. J Virol. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection: *J Virol* 76, 12735-46 (2002)
13. Muller L, S. McArdle, E. Derhovanessian, T. Flad, A. Knights, R. Rees, G. Pawelec. Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens. *Immunotherapy of Cancer*. Publisher Humana, Press (2007)
14. Theobald M, T. Ruppert, U. Kuckelkorn, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, Koszinowski UH, Kloetzel PM, Sherman LA: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. *J Exp Med.* 188, 1017-28 (1998)

15. Street M.D, T. Doan, K.A. Herd, R.W. Tindle: Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. *Immunol.* 106, 526–536 (2002)
16. Choi E.M, J.L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I.F. Hermans, J.D. Silk, F. Mirza, M.J. Palmowski, P.R. Dunbar, B.K. Jakobsen, A.K. Sewell, V. Cerundolo: High avidity antigen-specific CTL identified by CD8-independent tetramer staining. *J Immunol* 171, 5116-23 (2003)
17. Johnson L.A, B. Heemskerk, D.J. Powell Jr, C.J. Cohen, R.A. Morgan, M.E. Dudley, P.F. Robbins, S.A. Rosenberg: Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to non reactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. *J Immunol* 177, 6548-59 (2006)
18. Trautmann L, M. Rimbart, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville: Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. *J Immunol* 175, 6123-32 (2005)
19. Altmann D.M, D.C. Douek, A.J. Frater, C.M. Hetherington, H. Inoko, J.I. Elliott: The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. *J. Exp. Med.* 181, 867 (1995)
20. Woods A, H.Y. Chen, M.E. Trumbauer, A. Sirotina, R. Cummings, D.M. Zaller: Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. *J. Exp. Med* 180, 173 (1994)
21. Kong Y.M, C.S. David, L.C. Lomo, B.E. Fuller, R.W. Motte, A.A. Giraldo: Role of mouse and human class II transgenes in susceptibility to and protection against mouse autoimmune thyroiditis. *Immunogenetics* 46, 312 (1997)
22. Assudani D.P, R.B. Horton, M.G. Mathieu, S.E. McArdle, R.C. Rees: The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. *Cancer Immunol Immunother* 56, 70-80 (2007)
23. Janssen E.M, N.M. Droin, E.E. Lemmens, M.J. Pinkoski, S.J. Bensinger, B.D. Ehst, T.S. Griffith, D.R. Green, S.P. Schoenberger: CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature* 434, 88-93 (2005)
24. Wong S.B, R. Bos, L.A. Sherman: Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells. *J Immunol* 180, 3122-31 (2008)
25. Wilson C.C, B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, B.D. Livingston: Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. *J Virol* 75, 4195-207 (2001)
26. Boritz E, B.E. Palmer, B. Livingston, A. Sette, C.C. Wilson: Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. *J. Immunol* 170, 1106 (2003)
27. Sonderstrup G, A.P. Cope, S. Patel, M. Congia, N. Hain, F.C. Hall, S.L. Parry, L.H. Fugger, S. Michie, H.O. McDevitt: HLA class II transgenic mice: models of the human CD4+ T-cell immune response. *Immunol Rev* 172, 335-43 (1999)
28. Pajot A, V. Pancre, N. Fazilleau, M.L. Michel, G. Angyalosi, D.M. Ojcius, C. Auriault, F.A. Lemonnier, Y.C. Lone: Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules. *Int Immunol* 16, 1275-82 (2004)
29. Firat H, M. Cochet, P.S. Rohrllich, F. Garcia-Pons, S. Darche, O. Danos, F.A. Lemonnier, P. Langlade-Demoyen: Comparative analysis of the CD8 (+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. *Int Immunol* 14, 925-34 (2002)
30. Rojas J.M, S.E. McArdle, R.B. Horton, M. Bell, S. Mian, G. Li, S.A. Ali, R.C. Rees: Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1\*0101- and HLA-DRbeta1\*0401-restricted epitope from p53. *Cancer Immunol Immunother* 54, 243-53 (2005)
31. Rensing M.E, A. Sette, R.M. Brandt, J. Ruppert, P.A. Wentworth, M. Hartman, C. Oseroff, H.M. Grey, C.J. Melief, W.M. Kast: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through *in vivo* and *in vitro* immunogenicity studies of HLA-A\*0201-binding peptides. *J Immunol* 154, 5934-43 (1995)



32. Chandwani R, K.A Jordan, B.L. Shacklett, E. Pappasavvas, L.J. Montaner, M.G. Rosenberg, D.F. Nixon, J. K. Sandberg: Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infection. *Scand J Immunol* 59, 109-14 (2003)
33. Zhou H, Y. Luo, M. Mizutani, N. Mizutani, J.C. Becker, F.J. Primus, R. Xiang, R.A. Reisfeld. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. *J Clin Invest* 113, 1792-8 (2004)
34. Scardino A, M. Alimandi, P. Correale, S.G. Smith, R. Bei, H. Firat, M.G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, J. Marrocco, S. Chouaib, F.A. Lemonnier, A.M. Jackson, K. Kosmatopoulos: A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. *Cancer Res* 67, 7028-36 (2007)
35. Kuperwasser C, S. Dessain, B.E. Bierbaum, D. Garnet, K. Sperandio, G.P. Gauvin, S.P. Naber, R.A. Weinberg, M. Rosenblatt: A mouse model of human breast cancer metastasis to human bone. *Cancer Res* 65, 6130-8 (2005)
36. Morse H.C. Origins of Inbred Mice. *Academic Press* (1978)
37. Guy C.T, R.D. Cardiff, W.J. Muller: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol Cell Biol* 12, 954-61 (1992)
38. Wall E.M, K. Milne, M.L. Martin, P.H. Watson, P. Theiss, B.H. Nelson: Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. *Cancer Res* 67, 6442-50 (2007)
39. Degl'Innocenti E, M. Grioni, A. Boni, A. Camporeale, M.T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N.M. Greenberg, M. Bellone: Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. *Eur J Immunol* 35, 66-75 (2005)
40. Hess P.R, D. Boczkowski, S.K. Nair, D. Snyder, E. Gilboa: Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. *Cancer Immunol Immunother* 55, 672-83 (2006)
41. Geginat J, F. Sallusto, A. Lanzavecchia: Cytokine-driven proliferation and differentiation of human naïve, central memory and effector memory CD4+ T cells. *Pathol Biol* 51, 64-6 (2003)
42. Overwijk W.W, M.R. Theoret, S.E. Finkelstein, D.R. Surman, L.A. de Jong, F.A. Vyth-Dreese, T.A. DelleMijn, P.A. Antony, P.J. Spiess, D.C. Palmer, D.M. Heimann, C.A. Klebanoff, Z. Yu, L.N. Hwang, L. Feigenbaum, A.M. Kruisbeek, S.A. Rosenberg, N.P. Restifo: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. *J Exp Med* 198, 569-80 (2003)
43. Klebanoff C.A, L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A.R. Cardones, S.E. Finkelstein, D.C. Palmer, P.A. Antony, S.T. Hwang, S.A. Rosenberg, T.A. Waldmann, N.P. Restifo: Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proc Natl Acad Sci USA* 102, 9571-6 (2005)
44. Jonkers J, A. Berns: Conditional mouse models of sporadic cancer. *Nat Rev Cancer* 2, 251-65 (2002)
45. Lengagne R, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.G. Guillet, V.H. Engelhard, M.F. Avril, J.P. Abastado, A. Prevost-Blondel: Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. *J Immunol* 180, 130-7 (2008)
46. Ahmad M, R.C. Rees, S.E. McArdle, G. Li, S. Mian, C. Entwisle, P. Loudon, S.A. Ali: Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF. *Int J Cancer* 115, 951-9 (2005)
47. Rehli M. Of mice and men: species variations of Toll-like receptor expression. *Trends Immunol* 23, 375-8 (2002)
48. Muzio M, D. Bosisio, N. Polentarutti, G. D'amico, A. Stoppacciaro, R. Mancinelli, C. van't Veer, G. Penton-Rol, L.P. Ruco, P. Allavena, A. Mantovani: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. *J Immunol* 164, 5998-6004 (2000)
49. Matsuguchi T, T. Musikacharoen, T. Ogawa, Y. Yoshikai: Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. *J Immunol* 165, 5767-72 (2000)

50. Pajot A, M.L. Michel, N. Fazilleau, V. Pancre, C. Auriault, D.M. Ojcius, F.A. Lemonnier, Y.C. Lone: A mouse model of human adaptive immune functions: HLA-A2.1/HLA-DR1-transgenic H-2 class I/class II-knockout mice. *Eur J Immunol* 34, 3060-9 (2004)
51. Altmann D.M, D.C. Douek, A.J. Frater, C.M. Hetherington, H. Inoko, J.I. Elliott: The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. *J Exp Med* 181, 867-875 (1995)
52. Ito K, H.J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D.R. Bolin, R. Arceo, R. Campbell, F. Falcioni, D. Vidovic, J. Hammer, Z.A. Nagy: HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. *J Exp Med* 183, 2635-44 (1996)
53. Alexander J, C. Oseroff, J. Sidney, P. Wentworth, E. Keogh, G. Hermanson, F.V. Chisari, R.T. Kubo, H.M. Grey, A. Sette: Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. *J Immunol* 159, 4753-61 (1997)
54. Barra C, B. Perarnau, P. Gerlinger, M. Lemeur, A. Gillet, P. Gibier, F.A. Lemonnier: Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice. *J Immunol* 143, 3117-24 (1989)
55. Kalinke U, B. Arnold, G.J. Hämmerling: Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA B27. *Nature* 348, 642-4 (1990)
56. Gotoh M, H. Takasu, K. Harada, T. Yamaoka: Development of HLA-A2402/K (b) transgenic mice. *Int J Cancer* 100, 565-70 (2002)
57. Yamamoto K, Y. Fukui, Y. Esaki, T. Inamitsu, T. Sudo, K. Yamane, N. Kamikawaji, A. Kimura, T. Sasazuki: Functional interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T cells in HLA-DR and DQ transgenic mice. *J Exp Med* 180, 165-71 (1994)
58. Schonbach C, K. Nokihara, C.R. Bangham, A. Kariyone, S. Karaki, H. Shida, K. Takatsu, K. Egawa, K.H. Wiesmüller, M. Takiguchi: Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B\*3501 transgenic mice. *Virology* 226, 102-12 (1996)
59. Guy C.T, R.D. Cardiff, W.J. Muller: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol Cell Biol* 12, 954-61 (1992)
60. Rowse G.J, R.M. Tempero, M.L. VanLith, M.A. Hollingsworth, S.J. Gendler: Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. *Cancer Res* 58, 315-21 (1998)
61. Mukherjee P, C.S. Madsen, A.R. Ginardi, T.L. Tindler, F. Jacobs, J. Parker, B. Agrawal, B.M. Longenecker, S.J. Gendler: Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. *J Immunother* 26, 47-62 (2003)
62. Greenberg N.M, F. DeMayo, M.J. Finegold, D. Medina, W.D. Tilley, J.O. Aspinall, G.R. Cunha, A.A. Donjacour, R.J. Matusik, J.M. Rosen: Prostate cancer in a transgenic mouse. *Proc Natl Acad Sci USA* 92, 3439-43 (1995)
62. Abate-Shen C, M.M. Shen: Mouse models of prostate carcinogenesis. *Trends Genet* 18, S1-5 (2002)
63. Garbe A.I, B. Vermeer, J. Gamrekelashvili, R. von Wasielewski, F.R. Greten, A.M. Westendorf, J. Buer, R.M. Schmid, M.P. Manns, F. Korangy, T.F. Greten: Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. *Cancer Res* 66, 508-16 (2006)
64. Tuveson D.A, A.T. Shaw, N.A. Willis, D.P. Silver, E.L. Jackson, S. Chang, K.L. Mercer, R. Grochow, H. Hock, D. Crowley, S.R. Hingorani, T. Zaks, C. King, M.A. Jacobetz, L. Wang, R.T. Bronson, S.H. Orkin, R.A. DePinho, T. Jacks: Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell* 5, 375-87 (2004)
65. Flesken-Nikitin A, K.C. Choi, J.P. Eng, E.N. Schmidt, A.Y. Nikitin: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. *Cancer Res* 63, 3459-63 (2003)
66. Hinoi T, A. Akyol, B.K. Theisen, D.O. Ferguson, J.K. Greenson, B.O. Williams, K.R. Cho, E.R. Fearon: Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. *Cancer Res* 67, 9721-30 (2007)

67. Meuwissen R, A. Berns: Mouse models for human lung cancer. *Genes Dev* 19, 643-64 (2005)

68. Meuwissen R, S.C. Linn, R.I. Linnoila, J. Zevenhoven, W.J. Mooi, A. Berns: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. *Cancer Cell* 4, 181-9 (2003)

**Key Words:** Transgenic mice, genetically modified mice, immunotherapy, cancer.

**Send correspondence to:** Stephanie McArdle, The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, UK, Tel: +44 (0) 115 848 6684, Fax: +44 (0) 115 848 3384, E-mail: [stephanie.mcardle@ntu.ac.uk](mailto:stephanie.mcardle@ntu.ac.uk)

**Running title:** MHC transgenic mice compared to genetically modified mice

DRAFT

**Table 1.** Comparative relevance of both models

Model using mice transgenic for HLA molecules	Genetically engineered mice developing spontaneous tumors
Metastasize only in the lung when injected intravenously and rarely at other sites	Frequent metastasis with a distribution which often reflect those in human
Wrong microenvironment	Appropriate microenvironment
Relatively inexpensive labor	Labor intensive
Allow the identification of clinically relevant peptides	Peptides are specific for mice of the same strain
Allow the assessment of different vaccines strategies but response may differ depending on the tumor implantation.	Allow the assessment of different vaccine strategies with responses more relevant due to their correct localization.

**Table 2.** List of HLA-transgenic mice (non exhaustive)

HLA-type	Mice background	References
HLA-A2 H-2 class-I KO	C57BL/6	(3)
HLA-A2 and HLA-DR1 H-2 class-I/class-II KO	C57BL/6	(49)
HLA-A3 H-2 KO	C57BL/6	(3)
HLA-DR1	FVB/N	(50)
HLA-DR4/IE	C57BL/6	(51)
HLA-A11/ Kb	C57BL/6	(52)
HLA-B7/Kb and class-I KO	C57BL/6	(53)
HLA-A27/Kb	C57BL/6	(54)
HLA-A24 H-2 class-I KO	C57BL/6	(55)
HLA-DQ6 and HLA-DR51	C57BL/6	(56)
HLA-B35	C57BL/6	(57)

**Table 3.** Examples of existing spontaneous tumor models in mice

Cancer model	Genetic modifications	References
Breast Cancer	Mice expressing the polyomavirus middle-T oncogene driven by the mouse mammary tumor virus (MMTV) long-terminal repeat (LTR) these develop spontaneous mammary carcinomas. MUC1 transgenic mice (MUC1.Tg) expressing the human MUC1 antigen in a tissue-specific fashion similar to that in humans. MMT mice expressing the PyMT and the MUC1 antigen and develop spontaneous mammary carcinomas.	(58) (59) (60)
Prostate Cancer	C57BL/6 inbred TRAMP mice were generated by microinjection of a construct harboring a minimal rat probasin (PB) -426/+28 regulatory element to direct expression of the SV40 early genes (T and t antigens; Tag) to prostatic epithelium in a developmentally and hormonally regulated fashion.	(61) For a more comprehensive review on spontaneous prostate cancer refer to Abate-Shen C and Shen MM (62)
Pancreatic Adenocarcinoma	P53-deficient mice and TGF- $\alpha$ human growth hormone (hGH) fusion gene under the control of the Elastase (El) promoter (EL-TGF-a-hGH transgenic mice backcrossed on CD57BL/6. Develop rapidly growing tumors in the pancreas within 120 days after birth.	(63) (64)
Ovary Cancer	Cre-adenovirus/ p53+RB1 floxed recipients where more than 90% of the mice develop progressive and metastatic ovarian tumors	(65)
Colon adenocarcinoma	C57BL6/J mice carrying the ApcMin mutation were intercrossed with mice carrying the CDX2P 9.5-NLS Cre allele. These developed mainly colorectal tumors, with carcinomas seen in 6 of 36 (17%) of mice followed for 300 days.	(66)
Lung Cancers	Various models	(67) and (68)
Melanoma	MT-ret mice were crossed with AAD mice expressing a chimeric MHC class I composed of the $\alpha 1$ and $\alpha 2$ domains of HLA-A*0201 and the 3 domain of H2-Dd (31) to produce MT-ret+/-/AAD+/- (MT-ret/AAD) mice. More than 85% of the MT-ret/AAD mice (n = 101) displayed tumors within 4 mo after birth, and 50% of them had several evident cutaneous nodules at day 64.	(44)

**Figure 1.** Cytotoxicity and proliferation assays were performed using splenocytes cells generated from HHDII/HLA-DR1 transgenic mice immunized with DC transiently transfected with pSHAME2a/HAGE and re-stimulated with either HAGE-derived class I peptide (126) (A), or HAGE-derived class II peptide 338 (B) or peptide 506 (C). Standard 4hrs chromium release assay was carried out after *in vitro* re-stimulation of immunized cells with immunogenic HAGE-derived class I peptides. Cytokine analysis was carried out on supernatants harvested on day 3 and 5 of the *in vitro* re-stimulation with HAGE peptide (data not shown). Specific killing can be seen against target cells pulsed with HAGE126 compared to those pulsed with an irrelevant one. Specific release of IFN $\gamma$  was also observed with all tested peptides mainly on day 3 with however also a production of IL-5 by peptide HAGE338 but only on day 3 (data not shown). Proliferation assays were carried out after *in vitro* re-stimulation of immunized cells with HAGE 338 (A) and HAGE 506 (B) followed by a resting period of one week with low level of murine IL-2. For the proliferation mature BM-DC pulsed with either the relevant or irrelevant peptide were co-cultured with the CD8<sup>+</sup> rested splenocytes for 60 hours with the addition of radio-active thymidine (<sup>3</sup>H) during the last 18 hours. Results are expressed in counts per minute (cpm) and as means of the quadruplicate wells. Specific proliferation could be detected when the cells from immunized animals were co-cultured with DC-pulsed with the specific HAGE-derived peptides whether it be HAGE338 or HAGE506. The addition of an HLA-DR antibody in the culture was able to specifically inhibit this proliferation for both peptides whereas isotype control was not. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 are the statistical differences between HAGE-derived peptides and Irrelevant determined by unpaired Student T test.

DRAFT

